PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-?-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDV RNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY

Wedemeyer, H.Yurdaydin, C.Ernst, S.Caruntu, F. A.Curescu, M. G.Yalcin, K.Akarca, U. S.2024-04-242024-04-2420140168-82781600-0641https://doi.org/10.1016/S0168-8278(14)60006-4https://hdl.handle.net/11468/1629249th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver -- APR 09-13, 2014 -- London, ENGLAND[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keyword]PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-?-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDV RNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDYPROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-?-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDV RNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDYConference Object601S2S3WOS:00036196170000510.1016/S0168-8278(14)60006-4Q1